These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 19337172

  • 1. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 2. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
    Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():285-91. PubMed ID: 16462713
    [Abstract] [Full Text] [Related]

  • 3. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT.
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [Abstract] [Full Text] [Related]

  • 4. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A, Amendola G, Pugliese U, Tartaglione I, Della Rocca F, Cinque P, Nobili B, Perrotta S.
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [Abstract] [Full Text] [Related]

  • 5. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
    De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC, Italian Working Group on Endocrine Complications in Non-Endocrine Diseases.
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):471-80. PubMed ID: 16759032
    [Abstract] [Full Text] [Related]

  • 6. Endocrine complications in patients with Thalassaemia Major.
    Toumba M, Sergis A, Kanaris C, Skordis N.
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V, Eleftheriou A, Malaventura C, Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():249-55. PubMed ID: 16462705
    [Abstract] [Full Text] [Related]

  • 8. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 9. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M, Skordos G, Christou S.
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [Abstract] [Full Text] [Related]

  • 10. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A.
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
    Karamifar H, Shahriari M, Sadjadian N.
    East Mediterr Health J; 2003 Oct; 9(1-2):55-60. PubMed ID: 15562733
    [Abstract] [Full Text] [Related]

  • 12. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V, Rigoli L, Lacquaniti A, Salpietro V, Piraino B, Amorini M, Salpietro C, Arrigo T.
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casaldáliga J, Díaz de Heredia C, Olivé T, Bastida P.
    Med Clin (Barc); 1994 May 21; 102(19):721-4. PubMed ID: 8041200
    [Abstract] [Full Text] [Related]

  • 14. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, Terlizzi F, Guitarrini MR, Monti S, Maffei L, Losardo A, Pasin M, Toscano V.
    Ann Hematol; 2016 Apr 21; 95(5):757-63. PubMed ID: 26957357
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Endocrinopathies in patients with thalassemias.
    Al-Elq AH, Al-Saeed HH.
    Saudi Med J; 2004 Oct 21; 25(10):1347-51. PubMed ID: 15494799
    [Abstract] [Full Text] [Related]

  • 17. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb 21; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 18. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K, Tzoumari I, Pappa C.
    Blood Cells Mol Dis; 2011 Jun 15; 47(1):33-40. PubMed ID: 21531154
    [Abstract] [Full Text] [Related]

  • 19. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Jun 15; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 20. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases.
    Clin Endocrinol (Oxf); 1995 Jun 15; 42(6):581-6. PubMed ID: 7634497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.